<DOC>
	<DOCNO>NCT02015988</DOCNO>
	<brief_summary>To test hypothesis early ( within 5-21 day index event ) administration combine lipid-lowering therapy extremely high risk population patient type 2 diabetes mellitus ( T2DM ) hypertriglyceridemia ( HTG ) experience acute coronary syndrome ( ACS ) effective well tolerate achievement contemporary strict requirement triglyceride ( TG ) level independent risk factor case HTG diabetes .</brief_summary>
	<brief_title>Simvastatin Fenofibrate v Simvastatin Alone Patients With Type 2 Diabetes Mellitus Acute Coronary Syndrome</brief_title>
	<detailed_description>The primary objective parallel group study demonstrate combine therapy simvastatin fenofibrate superior compare monotherapy simvastatin base comparison change TG level 12 week treatment compare baseline . Secondary objective compare treatment alternative combination therapy simvastatin fenofibrate simvastatin monotherapy respect achievement European Society Cardiology 2011 ( ESC 2011 ) non-HDL-C target ( less 2,6 mmol/l ) , change apolipoprotein B/apolipoprotein A1 ( apoB/apoA1 ) ratio , High-Density Lipoprotein-Cholesterol ( HDL-C ) , Low-Density Lipoprotein-Cholesterol ( LDL-C ) Uric Acid ( UA ) 12 week 52 week ( 1 year ) treatment compare baseline .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Type 2 Diabetes Mellitus Fasting triglycerides ≥ 1,7 mmol/l Acute coronary syndrome least 5 maximum 21 day inclusion If previously treat statin therapy , dose equivalent 40 mg simvastatin inclusion In case previous statin therapy , last LDLC measurement event ≤ 2,6 mmol/l Written inform consent obtain Heart failure IV class ( NYHA ) Acute decompensated heart failure Life expectancy 1 year Chronic kidney disease ( CKD ) Estimated glomerular filtration rate ( eGFR ) &lt; 30 ml/min/1.73m2 Severe chronic liver diseases Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) &gt; 3 Upper Limit Normal ( ULN ) Known gallbladder disease , include cholecystolithiasis Creatinphosphokinase ( CPK ) &gt; 5 ULN baseline Chronic acute pancreatitis exception acute pancreatitis due severe hypertriglyceridemia Known photoallergy phototoxic reaction treatment fibrates ketoprofen , Known allergy peanut arachis oil soya lecithin relate product Hypersensitivity simvastatin fenofibrate excipients investigational drug Concomitant administration potent cytochrome P450 isoenzyme 3A4 inhibitor ( e.g . itraconazole , ketoconazole , fluconazole , posaconazole , Human Immunodeficiency Virus ( HIV ) protease inhibitor ( e.g . nelfinavir ) , erythromycin , clarithromycin , telithromycin nefazodone ) Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Hypertriglyceridemia</keyword>
	<keyword>Simvastatin</keyword>
	<keyword>Fenofibrate</keyword>
</DOC>